Epiomic Epidemiology Series: Hypertrophic Cardiomyopathy Forecast in 8 Major Markets 2015-2025

August 2015 | 38 pages | ID: EB9D536690EEN
Black Swan Analysis limited

Abstracts

Hypertrophic cardiomyopathy (HCM) is a disease that contains an autosomal dominant inheritance pattern and is a moderately common “transmitted” genetic disease. The disease, characterized by hypertrophy in the left ventricle, cannot be explained by the presence of other clinical symptoms, such as hypertension. This report provides the current prevalent population for HCM across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of HCM. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of HCM have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for HCM include:

• Chronic heart failure
• Angina pectoris
• Atrial fibrillation
• Tachycardia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global HCM’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of HCM and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on HCM’s prevalent population.
• Examination of the prevalence of the different causative gene mutations for HCM.
• Identify sub-populations within HCM which require treatment.
• Gain an understanding of the specific markets that have the largest number of HCM patients.

Contents

Overview
Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis &Clinical Course
Key Co-morbid Conditions/Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Hypertrophic Cardiomyopathy
Main Type and Cardiac Features of Hypertrophic Cardiomyopathy
  HCM main type
  HCM by symptoms
  Cardiac features of HCM
  HCM related death
Significant Co-morbid Conditions Associated with HCM
Gene Mutations within HCM
References
Appendix

List Of Tables

LIST OF TABLES & FIGURES

1. Prevalence of HCM, total (000s)
2. Prevalence of HCM, males (000s)
3. Prevalence of HCM, females (000s)
4. HCM by main type – familial vs. sporadic, total (000s)
5. Symptomatic HCM, total (000s)
6. Dyspnoea within symptomatic HCM (000s)
7. Clinical heart failure within symptomatic HCM (000s)
8. Angina pectoris within symptomatic HCM (000s)
9. Syncope within symptomatic HCM (000s)
10. Paroxysmal supraventricular tachycardia within symptomatic HCM (000s)
11. Dynamic Left Ventricular Outflow obstruction (LVOT) in patients with HCM, total (000s)
12. Maximum Left Ventricular Thickness (LVT) in patients with HCM, total (000s)
13. Causes of death associated with HCM, total (000s)
14. Prevalence of hypertension in patients with HCM, total (000s)
15. Prevalence of atrial fibrillation in patients with HCM, total (000s)
16. Key gene mutation within HCM patients, total (000s)
17. USA Prevalence of HCM by 5-yr age cohort, males (000s)
18. USA Prevalence of HCM by 5-yr age cohort, females (000s)
19. France Prevalence of HCM by 5-yr age cohort, males (000s)
20. France Prevalence of HCM by 5-yr age cohort, females (000s)
21. Germany Prevalence of HCM by 5-yr age cohort, males (000s)
22. Germany Prevalence of HCM by 5-yr age cohort, females (000s)
23. Italy Prevalence of HCM by 5-yr age cohort, males (000s)
24. Italy Prevalence of HCM by 5-yr age cohort, females (000s)
25. Spain Prevalence of HCM by 5-yr age cohort, males (000s)
26. Spain Prevalence of HCM by 5-yr age cohort, females (000s)
27. United Kingdom Prevalence of HCM by 5-yr age cohort, males (000s)
28. United Kingdom Prevalence of HCM by 5-yr age cohort, females (000s)
29. Brazil Prevalence of HCM by 5-yr age cohort, males (000s)
30. Brazil Prevalence of HCM by 5-yr age cohort, females (000s)
31. Japan Prevalence of HCM by 5-yr age cohort, males (000s)
32. Japan Prevalence of HCM by 5-yr age cohort, females (000s)